Business
Faron Announces Two Bexmarilimab Abstracts Accepted At Ash 2025, Including An Oral Presentation On Treatment Efficacy
This acceptance marks the fifth major medical conference this year to feature bexmarilimab in an oral session, reinforcing the drug's unique mechanism in hematologic malignancies and potential to improve patient outcomes. TURKU, FI / ACCESS Newswire ...
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"This acceptance marks the fifth major medical conference this year to feature bexmarilimab in an oral session, reinforcing the drug's unique mechanism in hematologic malignancies and potential to improve patient outcomes.","length":225,"tagName":"p"},{"type":"text","content":"TURKU, FI / ACCESS Newswire / November 4, 2025 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel treatments for medical conditions with significant unmet needs, today announced that two abstracts featuring data from the Phase 1/2 BEXMAB study have been accepted for presentation at the American Society of Hematology (ASH) 2025 Annual Meeting.","length":416,"tagName":"p"},{"type":"text","content":"Highlighting the growing body of evidence for bexmarilimab, an abstract detailing the overall efficacy, molecular, and translational analysis of bexmarilimab in combination with azacitidine in patients with TP53-mutated (mTP53) higher-risk myelodysplastic syndromes (HR-MDS) has been selected for an oral presentation. This patient population has a particularly poor prognosis and represents a high unmet medical need. The second abstract, accepted as a poster presentation, reports on transfusion independence, hematological improvement, and associated safety outcomes from the BEXMAB study, further characterizing the clinically meaningful benefits and differentiated biology of the combination.","length":697,"tagName":"p"},{"type":"text","content":""The continued recognition of the bexmarilimab program by prestigious congresses like ASH is a testament to the strength and consistency of the data we are generating," said Dr. Juho Jalkanen, CEO of Faron. "The encouraging data in the challenging mutated TP53 patient population, underscores the potential of bexmarilimab to address a significant unmet need in hematologic malignancies. This marks a significant step forward in our mission to bring novel immunotherapies to patients who currently have very few options."","length":541,"tagName":"p"},{"type":"text","content":"The presentation at ASH marks the fifth major international medical conference in 2025 where bexmarilimab data has been accepted for an oral presentation, following sessions at the MDS Foundation, the European Hematology Association (EHA) Congress, the European Socie...